A phase II Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline <i>PTEN</i> -Inactivating Mutations
Jordi Rodón, Pauline Funchain, Theodore W. Laetsch, Hendrik‐Tobias Arkenau, Alice Hervieu, Christian F. Singer, Yonina R. Murciano‐Goroff, Sant P. Chawla, Kristin Anthony, Ikuo Yamamiya, Mei Liu, Abdel‐Baset Halim, Karim A. Benhadji, Osamu Takahashi, Suzette Delaloge
Abstract
PTEN acts as a potent tumor suppressor within the PI3K/AKT/mTOR pathway. Germline mutations in the PTEN gene are a hallmark of PTEN hamartoma tumor syndrome, which includes Cowden syndrome, where they appear to elevate lifetime risk of cancer. Targeted AKT directed therapy has been proposed as an effective approach in cancer patients having germline PTEN mutations. The mechanism of action, safety and dosing regimen for the novel allosteric AKT inhibitor TAS-117 have been explored in a phase I study in Japan in which activity was observed against certain tumor types. Here we describe the study protocol of an international, two-part phase II study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations.